Who are Durvalumab + Olaparib phase's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/durvalumab-olaparib-phase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Durvalumab + Olaparib phase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab + Olaparib phase (Durvalumab + Olaparib phase) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor + PARP inhibitor combination. Area: Oncology.

phase 3 PD-L1 inhibitor + PARP inhibitor combination PD-L1 and PARP1/PARP2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Durvalumab + Olaparib phase (Durvalumab + Olaparib phase) — AstraZeneca. Durvalumab blocks PD-L1 to enhance immune activation while olaparib inhibits PARP to impair DNA repair, together leveraging immunotherapy and synthetic lethality in homologous recombination-deficient tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Durvalumab + Olaparib phase TARGET	Durvalumab + Olaparib phase	AstraZeneca	phase 3	PD-L1 inhibitor + PARP inhibitor combination	PD-L1 and PARP1/PARP2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor + PARP inhibitor combination class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Durvalumab + Olaparib phase — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab-olaparib-phase. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing